Citations

Clear

6273 citation(s) found for "To, Andrew".

Prevalence Of Low Energy Availability In A Collegiate Men's Gymnastics Team
Kuhlman, Nicholas M., Wilcox, Luke, Jones, Margaret T. , Magee, Meghan K., Fields, Jennifer B. , Jagim, Andrew R.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 16, 2024 | Volume: 56 | Issue: 10S | Pages: 629-629

10.1249/01.mss.0001057932.12836.9b Get It

Do obese patients undergoing surgery for grade 1 spondylolisthesis have worse outcomes at 5 years’ follow-up? A QOD study
Zammar, Samer G. , Yee, Timothy J., Patel, Arati , Le, Vivian , Alan, Nima , Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Knightly, Jack, Fu, Kai-Ming, Foley, Kevin T. , Shaffrey, Mark E., Bydon, Mohamad , Chou, Dean , Chan, Andrew K. , Meyer, Scott A., Shaffrey, Christopher I. , Slotkin, Jonathan R., Haid, Regis W., Glassman, Steven D. , Virk, Michael S. , Mummaneni, Praveen V. , Ambati, Vardhaan , Fu, Kai-Ming, Asher, Anthony L., Wang, Michael , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | September 14, 2024 | Volume: 41 | Issue: 5 | Pages: 564-571

10.3171/2024.5.spine24125 | PMID 39270316 Get It

OBJECTIVE The long-term effects of increased body mass index (BMI) on surgical outcomes are unknown for patients who undergo surgery for low-grade lumbar spondylolisthesis. The goal of this study was to assess long-term outcomes in obese versus nonobese patients after surgery for grade 1 spondylolisthesis. METHODS Patients who underwent surgery for grade 1 spondylolisthesis at the Quality Outcomes Database’s 12 highest enrolling sites (SpineCORe group) were identified. Long-term (5-year) outcomes were compared for patients with BMI ≥ 35 versus BMI < 35. RESULTS In total, 608 patients (57.6% female) were included. Follow-up was 81% (excluding patients who had died) at 5 years. The BMI ≥ 35 cohort (130 patients, 21.4%) was compared to the BMI < 35 cohort (478 patients, 78.6%). At baseline, patients with BMI ≥ 35 were more likely to be younger (58.5 ± 11.4 vs 63.2 ± 12.0 years old, p < 0.001), to present with both back and leg pain (53.8% vs 37.0%, p = 0.002), and to require ambulation assistance (20.8% vs 9.2%, p < 0.001). Furthermore, the cohort with BMI ≥ 35 had worse baseline patient-reported outcomes including visual analog scale (VAS) back (7.6 ± 2.3 vs 6.5 ± 2.8, p < 0.001) and leg (7.1 ± 2.6 vs 6.4 ± 2.9, p = 0.031) pain, disability measured by the Oswestry Disability Index (ODI) (53.7 ± 15.7 vs 44.8 ± 17.0, p < 0.001), and quality of life on EuroQol-5D (EQ-5D) questionnaire (0.47 ± 0.22 vs 0.56 ± 0.22, p < 0.001). Patients with BMI ≥ 35 were more likely to undergo fusion (85.4% vs 74.7%, p = 0.01). There were no significant differences in 30- and 90-day readmission rates (p > 0.05). Five years postoperatively, there were no differences in reoperation rates or the development of adjacent-segment disease for patients in either BMI < 35 or ≥ 35 cohorts who underwent fusion (p > 0.05). On multivariate analysis, BMI ≥ 35 was a significant risk factor for not achieving minimal clinically important differences (MCIDs) for VAS leg pain (OR 0.429, 95% CI 0.209–0.876, p = 0.020), but BMI ≥ 35 was not a predictor for achieving MCID for VAS back pain, ODI, or EQ-5D at 5 years postoperatively. CONCLUSIONS Both obese and nonobese patients benefit from surgery for grade 1 spondylolisthesis. At the 5-year time point, patients with BMI ≥ 35 have similarly low reoperation rates and achieve rates of satisfaction and MCID for back pain (but not leg pain), disability (ODI), and quality of life (EQ-5D) that are similar to those in patients with a BMI < 35.
Do class III obese patients achieve similar outcomes and satisfaction to nonobese patients following surgery for cervical myelopathy? A QOD study
Park, Christine , Bhowmick, Deb A. , Shaffrey, Christopher I., Bisson, Erica F. , Bydon, Mohamad , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Schüpper, Alexander J. , Tumialán, Luis M. , Turner, Jay D. , Chan, Andrew K. , Chou, Dean , Haid, Regis W., Mummaneni, Praveen V., Gottfried, Oren N., Shaffrey, Christopher I. , Fu, Kai-Ming, Park, Paul , Uribe, Juan S. , Mummaneni, Praveen V.

Mayo Clinic

Journal of Neurosurgery: Spine | September 14, 2024 | Volume: 41 | Issue: 5 | Pages: 604-610

10.3171/2024.6.spine24126 | PMID 39270317 Get It

OBJECTIVE The aim of this study was to compare the rate of achievement of the minimal clinically important difference (MCID) in patient-reported outcomes (PROs) and satisfaction between cervical spondylotic myelopathy (CSM) patients with and without class III obesity who underwent surgery. METHODS The authors analyzed patients from the 14 highest-enrolling sites in the prospective Quality Outcomes Database CSM cohort. Patients were dichotomized based on whether or not they were obese (class III, BMI ≥ 35 kg/m 2 ). PROs including visual analog scale (VAS) neck and arm pain, Neck Disability Index (NDI), modified Japanese Orthopaedic Association (mJOA), EQ-5D, and North American Spine Society patient satisfaction scores were collected at baseline and 24 months after cervical spine surgery. RESULTS Of the 1141 patients with CSM who underwent surgery, 230 (20.2%) were obese and 911 (79.8%) were not. The 24-month follow-up rate was 87.4% for PROs. Patients who were obese were younger (58.1 ± 12.1 years vs 61.2 ± 11.6 years, p = 0.001), more frequently female (57.4% vs 44.9%, p = 0.001), and African American (22.6% vs 13.4%, p = 0.002) and had a lower education level (high school or less: 49.1% vs 40.8%, p = 0.002) and a higher American Society of Anesthesiologists grade (2.7 ± 0.5 vs 2.5 ± 0.6, p < 0.001). Clinically at baseline, the obese group had worse neck pain (VAS score: 5.7 ± 3.2 vs 5.1 ± 3.3), arm pain (VAS score: 5.4 ± 3.5 vs 4.8 ± 3.5), disability (NDI score: 42.7 ± 20.4 vs 37.4 ± 20.7), quality of life (EQ-5D score: 0.54 ± 0.22 vs 0.56 ± 0.22), and function (mJOA score: 11.6 ± 2.8 vs 12.2 ± 2.8) (all p < 0.05). At the 24-month follow-up, however, there was no difference in the change in PROs between the two groups. Even after accounting for relevant covariates, no significant difference in achievement of MCID and satisfaction was observed between the two groups at 24 months. CONCLUSIONS Despite the class III obese group having worse baseline clinical presentations, the two cohorts achieved similar rates of satisfaction and MCID in PROs. Class III obesity should not preclude and/or delay surgical management for patients who would otherwise benefit from surgery for CSM.
Transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and cardiogenic shock
Ismayl, Mahmoud , Ahmed, Hasaan , Eleid, Mackram F. , Guerrero, Mayra , Rihal, Charanjit S. , Ismayl, Mahmoud , Goldsweig, Andrew M. , Guerrero, Mayra , Rihal, Charanjit S.

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | September 13, 2024 | Volume: 13 | Issue: 10 | Pages: 685-698

10.1093/ehjacc/zuae103 | PMID 39268865 Get It

Abstract Aims Patients with aortic stenosis (AS) and cardiogenic shock (CS) are an extremely high-risk population with a poor prognosis in the absence of definitive therapy. We aimed to compare the outcomes of transcatheter aortic valve replacement (TAVR) with those of surgical aortic valve replacement (SAVR) in patients with AS–CS. Methods and results We queried the Nationwide Readmission Database (2016–21) to identify patients hospitalized for AS–CS who underwent isolated TAVR or SAVR. In-hospital outcomes of TAVR vs. SAVR were compared using multivariable regression and propensity-matching analyses. Ninety-day readmissions were compared using a Cox proportional hazards regression model. A total of 16 161 patients were hospitalized for AS–CS, of whom 6470 (40.0%) underwent isolated TAVR and 9691 (60.0%) underwent isolated SAVR. From 2016 through 2021, the proportion of TAVR increased from 29.5 to 46.5% and the proportion of SAVR correspondingly decreased in AS–CS (Ptrend &lt; 0.01). After adjustment for baseline characteristics, TAVR was associated with lower odds of stroke [adjusted odds ratio (aOR) 0.63, 95% confidence interval (CI) 0.47–0.84], acute kidney injury (aOR 0.80, 95% CI 0.69–0.93), and major bleeding (aOR 0.54, 95% CI 0.40–0.71) and higher odds of vascular complications (aOR 1.56, 95% CI 1.23–1.97) compared with SAVR. In-hospital mortality, myocardial infarction, permanent pacemaker placement, and 90-day all-cause and heart failure readmissions showed similar rates between TAVR and SAVR. However, hospital length of stay was shorter and total costs and non-home discharges were lower with TAVR than with SAVR. Conclusion This nationwide observational analysis showed that TAVR is increasingly performed in patients with AS–CS and is associated with similar rates of in-hospital mortality and 90-day readmissions but lower rates of in-hospital complications and resource utilization compared with SAVR.
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis
Abro, Brooj , Maurer, Matthew J. , Burack, Richard , Chapman, Jennifer R. , Cohen, Jonathon B. , Friedberg, Jonathan W. , Inghirami, Giorgio , Lossos, Izidore S. , Martin, Peter W., McDonnell, Timothy J. , Riska, Shaun M., Flowers, Christopher R. , Burack, W Richard , Cohen, Jonathon B , Inghirami, Giorgio , Link, Brian K , Lossos, Izidore S , Nastoupil, Loretta J , Vega, Francisco , Cerhan, James R , Feldman, Andrew L , Maurer, Matthew , Habermann, Thomas M. , Kahl, Brad S. , Larson, Melissa C. , Link, Brian K. , Martin, Peter, Nastoupil, Loretta J. , Syrbu, Sergei , Vega, Francisco , Vij, Kiran R , Cerhan, James R. , Jaye, David L. , Feldman, Andrew L.

Mayo Clinic

Blood | September 10, 2024 | Volume: 144 | Issue: 19 | Pages: 2063-2066

10.1182/blood.2024025681 | PMID 39255410 Get It

Abstract Recent introduction of 2 different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial enrollment. Data from a large cohort reflecting real-world clinical practice suggest that differences between the classifications will affect &lt;1% of non-Hodgkin lymphomas.
Endoscopic, Endonasal, Transsphenoidal, Transclival Approach for Resection of Odontoid Process: 2-Dimensional Operative Video
Zervos, Thomas M. , Cho, Steve S. , Samiappan, Sathish Prabu Sathyamangalam , Little, Andrew S. , Santarelli, Griffin D., Ronecker, Jennifer S., McClendon, Jamal, Sathyamangalam Samiappan, Sathish Prabu

Mayo Clinic

Operative Neurosurgery | September 9, 2024 | Volume: 28 | Issue: 1 | Pages: 132-132

10.1227/ons.0000000000001350 | PMID 39248517 Get It

Does comorbid depression and anxiety portend poor long-term outcomes following surgery for lumbar spondylolisthesis? Five-year analysis of the Quality Outcomes Database
DiDomenico, Joseph D., Virk, Michael S., Godzik, Jakub , Johnson, Sarah E. , Bydon, Mohamad , Mummaneni, Praveen V. , Bisson, Erica F. , Glassman, Steven D. , Chan, Andrew K. , Chou, Dean , Fu, Kai-Ming, Shaffrey, Christopher I., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Knightly, John J. , Shaffrey, Mark E., Slotkin, Jonathan R., Haid, Regis W., Turner, Jay D. , Farber, Samuel Harrison , Virk, Michael S., Shaffrey, Christopher I. , Park, Paul , Uribe, Juan S.

Mayo Clinic

Journal of Neurosurgery: Spine | September 7, 2024 | Volume: 41 | Issue: 5 | Pages: 579-588

10.3171/2024.5.spine24325 | PMID 39241264 Get It

OBJECTIVE Depression and anxiety are associated with poor outcomes following spine surgery. However, the influence of these conditions on achieving a minimal clinically important difference (MCID) following lumbar spine surgery, as well as the potential compounding effects of comorbid depression and anxiety, is not well understood. This study explores the impact of comorbid depression and anxiety on long-term clinical outcomes following surgical treatment for degenerative lumbar spondylolisthesis. METHODS This study was a retrospective analysis of the multicenter, prospectively collected Quality Outcomes Database (QOD). Patients with surgically treated grade 1 lumbar spondylolisthesis from 12 centers were included. Preoperative baseline characteristics and comorbidities were recorded, including self-reported depression and/or anxiety. Pre- and postoperative patient-reported outcomes (PROs) were recorded: the numeric rating scale (NRS) score for back pain (NRS-BP), NRS score for leg pain (NRS-LP), Oswestry Disability Index (ODI), and EQ-5D. Patients were grouped into 3 cohorts: no self-reported depression or anxiety (non-SRD/A), self-reported depression or anxiety (SRD/A), or presence of both comorbidities (SRD+A). Changes in PROs over time, satisfaction rates, and rates of MCID were compared. A multivariable regression analysis was performed to establish independent associations. RESULTS Of the 608 patients, there were 452 (74.3%) with non-SRD/A, 81 (13.3%) with SRD/A, and 75 (12.3%) with SRD+A. Overall, 91.8% and 80.4% of patients had ≥ 24 and ≥ 60 months of follow-up, respectively. Baseline PROs were universally inferior for the SRD+A cohort. However, at 60-month follow-up, changes in all PROs were greatest for the SRD+A cohort, resulting in nonsignificant differences in absolute NRS-BP, NRS-LP, ODI, and EQ-5D across the 3 groups. MCID was achieved for the SRD+A cohort at similar rates to the non-SRD/A cohort. All groups achieved > 80% satisfaction rates with surgery without significant differences across the cohorts (p = 0.79). On multivariable regression, comorbid depression and anxiety were associated with worse baseline PROs, but they had no impact on 60-month PROs or 60-month achievement of MCIDs. CONCLUSIONS Despite lower baseline PROs, patients with comorbid depression and anxiety achieved comparable rates of MCID and satisfaction after surgery for lumbar spondylolisthesis to those without either condition. This quality-of-life benefit was durable at 5-year follow-up. These data suggest that patients with self-reported comorbid depression and anxiety should not be excluded from consideration of surgical intervention and often substantially benefit from surgery.
Comparative analysis of patient-reported outcomes in myelopathy and myeloradiculopathy: a Quality Outcomes Database study
Bisson, Erica F. , Sherrod, Brandon A. , Dru, Alexander, Chan, Andrew K. , Shaffrey, Christopher I., Gottfried, Oren N., Bydon, Mohamad , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Tumialán, Luis M. , Turner, Jay D. , Chou, Dean , Haid, Regis W., Mummaneni, Praveen V., Porche, Ken M. , Shaffrey, Christopher I. , Fu, Kai-Ming, Uribe, Juan S. , Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | September 7, 2024 | Volume: 41 | Issue: 6 | Pages: 734-745

10.3171/2024.5.spine24170 | PMID 39241256 Get It

OBJECTIVE Myelopathy in the cervical spine can present with diverse symptoms, many of which can be debilitating for patients. Patients with radiculopathy symptoms demonstrate added complexity because of the overlapping symptoms and treatment considerations. The authors sought to assess outcomes in patients with myelopathy presenting with or without concurrent radiculopathy. METHODS The Quality Outcomes Database, a prospectively collected multi-institutional database, was used to analyze demographic, clinical, and surgical variables of patients presenting with myelopathy or myeloradiculopathy as a result of degenerative pathology. Outcome measures included arm (VAS-arm) and neck (VAS-neck) visual analog scale (VAS) scores, modified Japanese Orthopaedic Association (mJOA) scale score, EuroQol VAS (EQ-VAS) score, and Neck Disability Index (NDI) at 3, 12, and 24 months compared with baseline. RESULTS A total of 1015 patients were included in the study: 289 patients with myelopathy alone (M0), 239 with myeloradiculopathy but no arm pain (MRAP−), and 487 patients with myeloradiculopathy and arm pain (MRAP+). M0 patients were older than the myeloradiculopathy cohorts combined (M0 64.2 vs MRAP− + MRAP+ 59.5 years, p < 0.001), whereas MRAP+ patients had higher BMI and a greater incidence of current smoking compared with the other cohorts. There were more anterior approaches used in in MRAP+ patients and more posterior approaches used in M0 patients. In severely myelopathic patients (mJOA scale score ≤ 10), posterior approaches were used more often for M0 (p < 0.0001) and MRAP+ (p < 0.0001) patients. Patients with myelopathy and myeloradiculopathy both exhibited significant improvement at 1 and 2 years across all outcome domains. The amount of improvement did not vary based on surgical approach. In comparing cohort outcomes, postoperative outcome differences were associated with patient-reported scores at baseline. CONCLUSIONS Patients with myelopathy and those with myeloradiculopathy demonstrated significant and similar improvement in arm and neck pain scores, myelopathy, disability, and quality of life at 3 months that was sustained at 1- and 2-year follow-up intervals. More radicular symptoms and arm pain increased the likelihood of a surgeon choosing an anterior approach, whereas more severe myelopathy increased the likelihood of approaching posteriorly. Surgical approach itself was not an independent predictor of outcome.
The Acute Kidney Intervention and Pharmacotherapy (AKIP) List: Standardized List of Medications That Are Renally Eliminated and Nephrotoxic in the Acutely Ill
Frazee, Erin N. , Gaggani, Alexis M., Hernandez, Brandy N., Amatullah, Nabihah, Culley, Colleen M., Stottlemyer, Britney A. , Murugan, Raghavan, Ozrazgat‐Baslanti, Tezcan , Kane‐Gill, Sandra L. , Group, For the MEnD-AKI Study, Frazee, Erin N , Kane-Gill, Sandra L , Bihorac, Azra , Kellum, John A. , Kashani, Kianoush , Rule, Andrew D. , Group, For the MEnD-AKI Study

Mayo Clinic

Annals of Pharmacotherapy | September 6, 2024 | Volume: 59 | Issue: 4 | Pages: 371-377

10.1177/10600280241273191 | PMID 39230007 Get It

The objective of this project was to develop a standardized list of renally eliminated and potentially nephrotoxic drugs that will help inform initiatives to improve medication safety. Several available lists of medications from the published literature including original research articles and reviews, and from regulatory agencies, tertiary references, and clinical decision support systems were compiled, consolidated, and compared. Only systemically administered medications were included. Medication combinations were included if at least 1 active ingredient was considered renally dosed or potentially nephrotoxic. The medication list was reviewed for completeness and clinical appropriateness by a multidisciplinary team of individuals with expertise in critical care, nephrology, and pharmacy. An initial list of renally dosed and nephrotoxic drugs was created. After reconciliation and consensus from clinical experts, a standardized list of 681 drugs is proposed. The proposed evidence-based standardized list of renally dosed and potentially nephrotoxic drugs will be useful to harmonize epidemiologic and medication quality improvement studies. In addition, the list can be used for clinical purposes with surveillance in nephrotoxin stewardship programs. We suggest an iterative re-evaluation of the list with emerging literature and new medications on an approximately annual basis.